Evidence map›Paper›PMID 30542509›Full record

ArticleOncotarget2018

Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells.

Françoise Boudouresque, Carole Siret, Aurélie Dobric, Françoise Silvy, Philippe Soubeyran, Juan Iovanna, Dominique Lombardo, Yolande Berthois

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. MCPIP1 RNase and Its Multifaceted Role.International journal of molecular sciences · 2020
    Review
  4. Article
  5. Activity of MCPIP1 RNase in tumor associated processes.Journal of experimental & clinical cancer research : CR · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Françoise BoudouresqueAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Carole SiretAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Aurélie DobricAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Françoise SilvyAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Philippe SoubeyranPresent address: Aix-Marseille University, INSERM, CNRS, Institut Paoli-Calmettes, CRCM, Pancreatic Cancer Team, Marseille, France.
Juan IovannaPresent address: Aix-Marseille University, INSERM, CNRS, Institut Paoli-Calmettes, CRCM, Pancreatic Cancer Team, Marseille, France.
Dominique LombardoAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Yolande BerthoisAix-Marseille Univ, INSERM UMR 911, CRO2, Marseille, France.
Aix-Marseille Université · FRCentre de Recherche en Cancérologie de Marseille · FRInserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The microRNA-200 (miR-200) family is frequently down-regulated in tumors, including pancreatic adenocarcinomas (PDACs). In this study we have examined the mechanisms involved in the loss of miR-200s in tumoral pancreatic cells. Whereas miR-200 gene promoters appear methylated in mature miR-200 deficient cell lines, miR-200 precursors are detected in nuclear but not cytoplasmic compartment of these cells, indicating that promoter hypermethylation is not sufficient to explain the deficit of mature miR-200s. The ribonuclease Monocyte Chemotactic Protein-induced Protein-1 (MCPiP1) may counteract Dicer1 in miRNA maturation process. MCPiP1/Dicer1 mRNA and protein ratios appear higher in miR-200 deficient compared to miR-200 proficient cells, suggesting that MCPiP1 may compete with Dicer1 in mature miR-200 deficient cells. Inhibition of MCPiP1 allows the detection of miR-200 precursors in cytoplasm of miR-200 deficient cells, confirming its involvement in the loss of miR-200s. Also, reversion of MCPiP1/Dicer1 ratio by over-expression of Dicer1 in miR-200 deficient cells leads to the recovery of mature miR-200s. Finally, whereas human malignant pancreatic tissues (PDACs) express lower miR-200 levels than non malignant tissues (non-MPDs), MCPiP1/Dicer1 ratio appears higher in PDACs, when compared to non-MPDs, supporting the hypothesis that MCPiP1/Dicer1 ratio is determinant in regulating miR-200 maturation process in a subset of tumoral pancreatic cells.

Indexed as

dicer1MCPiP1micro-RNA-200pancreatic cancer

Identifiers

PMID30542509
PMCPMC6267598
OpenAlexW2900588193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.